High flow nasal cannula therapy in the pediatric home setting
Background High‐flow nasal cannula (HFNC) therapy may be better tolerated than traditional noninvasive ventilation (NIV) and is rapidly gaining acceptance in pediatric acute care. In Israel, HFNC is approved for domestic use. We aim to describe its indications, efficacy, parental satisfaction, and s...
Gespeichert in:
| Veröffentlicht in: | Pediatric pulmonology 2023-03, Vol.58 (3), p.941-948 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 948 |
|---|---|
| container_issue | 3 |
| container_start_page | 941 |
| container_title | Pediatric pulmonology |
| container_volume | 58 |
| creator | Ehrlich, Shay Golan Tripto, Inbal Lavie, Moran Cahal, Michal Shonfeld, Tommy Prais, Dario Levine, Hagit Mei‐Zahav, Meir Bar‐On, Ophir Gendler, Yulia Zalcman, Jonatan Sarsur, Eahab Aviram, Micha Goldbart, Aviv Stafler, Patrick |
| description | Background
High‐flow nasal cannula (HFNC) therapy may be better tolerated than traditional noninvasive ventilation (NIV) and is rapidly gaining acceptance in pediatric acute care. In Israel, HFNC is approved for domestic use. We aim to describe its indications, efficacy, parental satisfaction, and safety.
Methods
Retrospective study of children treated with home HFNC therapy in three pediatric centers. Data included demographic parameters, indication of use, weight and days of hospitalization before and after initiation. Safety, tolerability, and parental satisfaction were assessed via standardized telephone questionnaire.
Results
Median (interquartile range [IQR]) age of initiating home HFNC in 75 children was 8.3 (2.2, 29.6) months. Indications were obstructive sleep apnea (33; 44%), airway malacia (19; 25%), chronic lung disease (15; 20%), neuromuscular disease (4; 5%), and postextubation support (4; 5%). Weight standard deviation score rose from −2.3 pre‐HFNC to −1.7 at 6.7 months post‐HFNC initiation, p |
| doi_str_mv | 10.1002/ppul.26282 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2758114608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2758114608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3932-d6c8a85d92966785f5d1e641ccf966b4dcc085882a1d6c943158bedd06bf864b3</originalsourceid><addsrcrecordid>eNp90E9LwzAYBvAgipvTix9AAl5E6EzaJksOHmSoEwbu4M4lTdItI_1j0jL27U3t9ODB0xve_Hh4eQC4xmiKEYofmqaz05jGLD4BY4w4j1DK6SkYsxkhEWU0GYEL73cIhT-Oz8EooYSmmCVj8Lgwmy0sbL2HlfDCQimqqrMCtlvtRHOApuqfsNHKiNYZCbd1qaHXbWuqzSU4K4T1-uo4J2D98vwxX0TL99e3-dMykglP4khRyQQjisec0hkjBVFYhwOkLMIiT5WUiBHGYoED5WmCCcu1UojmBaNpnkzA3ZDbuPqz077NSuOltlZUuu58Fs8IwziliAV6-4fu6s5V4bqgZpTTFJFe3Q9Kutp7p4uscaYU7pBhlPWlZn2p2XepAd8cI7u81OqX_rQYAB7A3lh9-CcqW63WyyH0C2oVgH4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2776964058</pqid></control><display><type>article</type><title>High flow nasal cannula therapy in the pediatric home setting</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Ehrlich, Shay ; Golan Tripto, Inbal ; Lavie, Moran ; Cahal, Michal ; Shonfeld, Tommy ; Prais, Dario ; Levine, Hagit ; Mei‐Zahav, Meir ; Bar‐On, Ophir ; Gendler, Yulia ; Zalcman, Jonatan ; Sarsur, Eahab ; Aviram, Micha ; Goldbart, Aviv ; Stafler, Patrick</creator><creatorcontrib>Ehrlich, Shay ; Golan Tripto, Inbal ; Lavie, Moran ; Cahal, Michal ; Shonfeld, Tommy ; Prais, Dario ; Levine, Hagit ; Mei‐Zahav, Meir ; Bar‐On, Ophir ; Gendler, Yulia ; Zalcman, Jonatan ; Sarsur, Eahab ; Aviram, Micha ; Goldbart, Aviv ; Stafler, Patrick</creatorcontrib><description>Background
High‐flow nasal cannula (HFNC) therapy may be better tolerated than traditional noninvasive ventilation (NIV) and is rapidly gaining acceptance in pediatric acute care. In Israel, HFNC is approved for domestic use. We aim to describe its indications, efficacy, parental satisfaction, and safety.
Methods
Retrospective study of children treated with home HFNC therapy in three pediatric centers. Data included demographic parameters, indication of use, weight and days of hospitalization before and after initiation. Safety, tolerability, and parental satisfaction were assessed via standardized telephone questionnaire.
Results
Median (interquartile range [IQR]) age of initiating home HFNC in 75 children was 8.3 (2.2, 29.6) months. Indications were obstructive sleep apnea (33; 44%), airway malacia (19; 25%), chronic lung disease (15; 20%), neuromuscular disease (4; 5%), and postextubation support (4; 5%). Weight standard deviation score rose from −2.3 pre‐HFNC to −1.7 at 6.7 months post‐HFNC initiation, p < 0.001. Hospital admission days during the 2 months pre‐ versus post‐HFNC initiation were 22 (5.5, 60) and 5 (0, 14.7) respectively, p < 0.008. Median (IQR) parental satisfaction score was 5/5 (4, 5). Fifty of 60 (83%) respondents would recommend home HFNC to other families in a similar situation. There were no serious adverse events.
Conclusion
In our population, domestic HFNC appeared safe and well tolerated for a variety of indications. Its introduction was associated with improved weight gain, fewer hospitalization days and high parental satisfaction. Further work is required to characterize groups of children most likely to benefit from HFNC, as opposed to traditional modes of NIV.</description><identifier>ISSN: 8755-6863</identifier><identifier>EISSN: 1099-0496</identifier><identifier>DOI: 10.1002/ppul.26282</identifier><identifier>PMID: 36564183</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Cannula ; Child ; chronic lung disease ; high flow nasal cannula ; home therapy ; Humans ; Noninvasive Ventilation ; Oxygen Inhalation Therapy ; pediatric ; Pediatrics ; Respiration, Artificial ; Respiratory Insufficiency - therapy ; Retrospective Studies</subject><ispartof>Pediatric pulmonology, 2023-03, Vol.58 (3), p.941-948</ispartof><rights>2022 The Authors. published by Wiley Periodicals LLC.</rights><rights>2022 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3932-d6c8a85d92966785f5d1e641ccf966b4dcc085882a1d6c943158bedd06bf864b3</citedby><cites>FETCH-LOGICAL-c3932-d6c8a85d92966785f5d1e641ccf966b4dcc085882a1d6c943158bedd06bf864b3</cites><orcidid>0000-0001-8880-8212 ; 0000-0001-6259-405X ; 0000-0002-6683-0264 ; 0000-0002-4165-0144 ; 0000-0002-7063-4653 ; 0000-0001-7259-4539 ; 0000-0001-6772-5784</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fppul.26282$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fppul.26282$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36564183$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ehrlich, Shay</creatorcontrib><creatorcontrib>Golan Tripto, Inbal</creatorcontrib><creatorcontrib>Lavie, Moran</creatorcontrib><creatorcontrib>Cahal, Michal</creatorcontrib><creatorcontrib>Shonfeld, Tommy</creatorcontrib><creatorcontrib>Prais, Dario</creatorcontrib><creatorcontrib>Levine, Hagit</creatorcontrib><creatorcontrib>Mei‐Zahav, Meir</creatorcontrib><creatorcontrib>Bar‐On, Ophir</creatorcontrib><creatorcontrib>Gendler, Yulia</creatorcontrib><creatorcontrib>Zalcman, Jonatan</creatorcontrib><creatorcontrib>Sarsur, Eahab</creatorcontrib><creatorcontrib>Aviram, Micha</creatorcontrib><creatorcontrib>Goldbart, Aviv</creatorcontrib><creatorcontrib>Stafler, Patrick</creatorcontrib><title>High flow nasal cannula therapy in the pediatric home setting</title><title>Pediatric pulmonology</title><addtitle>Pediatr Pulmonol</addtitle><description>Background
High‐flow nasal cannula (HFNC) therapy may be better tolerated than traditional noninvasive ventilation (NIV) and is rapidly gaining acceptance in pediatric acute care. In Israel, HFNC is approved for domestic use. We aim to describe its indications, efficacy, parental satisfaction, and safety.
Methods
Retrospective study of children treated with home HFNC therapy in three pediatric centers. Data included demographic parameters, indication of use, weight and days of hospitalization before and after initiation. Safety, tolerability, and parental satisfaction were assessed via standardized telephone questionnaire.
Results
Median (interquartile range [IQR]) age of initiating home HFNC in 75 children was 8.3 (2.2, 29.6) months. Indications were obstructive sleep apnea (33; 44%), airway malacia (19; 25%), chronic lung disease (15; 20%), neuromuscular disease (4; 5%), and postextubation support (4; 5%). Weight standard deviation score rose from −2.3 pre‐HFNC to −1.7 at 6.7 months post‐HFNC initiation, p < 0.001. Hospital admission days during the 2 months pre‐ versus post‐HFNC initiation were 22 (5.5, 60) and 5 (0, 14.7) respectively, p < 0.008. Median (IQR) parental satisfaction score was 5/5 (4, 5). Fifty of 60 (83%) respondents would recommend home HFNC to other families in a similar situation. There were no serious adverse events.
Conclusion
In our population, domestic HFNC appeared safe and well tolerated for a variety of indications. Its introduction was associated with improved weight gain, fewer hospitalization days and high parental satisfaction. Further work is required to characterize groups of children most likely to benefit from HFNC, as opposed to traditional modes of NIV.</description><subject>Cannula</subject><subject>Child</subject><subject>chronic lung disease</subject><subject>high flow nasal cannula</subject><subject>home therapy</subject><subject>Humans</subject><subject>Noninvasive Ventilation</subject><subject>Oxygen Inhalation Therapy</subject><subject>pediatric</subject><subject>Pediatrics</subject><subject>Respiration, Artificial</subject><subject>Respiratory Insufficiency - therapy</subject><subject>Retrospective Studies</subject><issn>8755-6863</issn><issn>1099-0496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp90E9LwzAYBvAgipvTix9AAl5E6EzaJksOHmSoEwbu4M4lTdItI_1j0jL27U3t9ODB0xve_Hh4eQC4xmiKEYofmqaz05jGLD4BY4w4j1DK6SkYsxkhEWU0GYEL73cIhT-Oz8EooYSmmCVj8Lgwmy0sbL2HlfDCQimqqrMCtlvtRHOApuqfsNHKiNYZCbd1qaHXbWuqzSU4K4T1-uo4J2D98vwxX0TL99e3-dMykglP4khRyQQjisec0hkjBVFYhwOkLMIiT5WUiBHGYoED5WmCCcu1UojmBaNpnkzA3ZDbuPqz077NSuOltlZUuu58Fs8IwziliAV6-4fu6s5V4bqgZpTTFJFe3Q9Kutp7p4uscaYU7pBhlPWlZn2p2XepAd8cI7u81OqX_rQYAB7A3lh9-CcqW63WyyH0C2oVgH4</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Ehrlich, Shay</creator><creator>Golan Tripto, Inbal</creator><creator>Lavie, Moran</creator><creator>Cahal, Michal</creator><creator>Shonfeld, Tommy</creator><creator>Prais, Dario</creator><creator>Levine, Hagit</creator><creator>Mei‐Zahav, Meir</creator><creator>Bar‐On, Ophir</creator><creator>Gendler, Yulia</creator><creator>Zalcman, Jonatan</creator><creator>Sarsur, Eahab</creator><creator>Aviram, Micha</creator><creator>Goldbart, Aviv</creator><creator>Stafler, Patrick</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8880-8212</orcidid><orcidid>https://orcid.org/0000-0001-6259-405X</orcidid><orcidid>https://orcid.org/0000-0002-6683-0264</orcidid><orcidid>https://orcid.org/0000-0002-4165-0144</orcidid><orcidid>https://orcid.org/0000-0002-7063-4653</orcidid><orcidid>https://orcid.org/0000-0001-7259-4539</orcidid><orcidid>https://orcid.org/0000-0001-6772-5784</orcidid></search><sort><creationdate>202303</creationdate><title>High flow nasal cannula therapy in the pediatric home setting</title><author>Ehrlich, Shay ; Golan Tripto, Inbal ; Lavie, Moran ; Cahal, Michal ; Shonfeld, Tommy ; Prais, Dario ; Levine, Hagit ; Mei‐Zahav, Meir ; Bar‐On, Ophir ; Gendler, Yulia ; Zalcman, Jonatan ; Sarsur, Eahab ; Aviram, Micha ; Goldbart, Aviv ; Stafler, Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3932-d6c8a85d92966785f5d1e641ccf966b4dcc085882a1d6c943158bedd06bf864b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cannula</topic><topic>Child</topic><topic>chronic lung disease</topic><topic>high flow nasal cannula</topic><topic>home therapy</topic><topic>Humans</topic><topic>Noninvasive Ventilation</topic><topic>Oxygen Inhalation Therapy</topic><topic>pediatric</topic><topic>Pediatrics</topic><topic>Respiration, Artificial</topic><topic>Respiratory Insufficiency - therapy</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ehrlich, Shay</creatorcontrib><creatorcontrib>Golan Tripto, Inbal</creatorcontrib><creatorcontrib>Lavie, Moran</creatorcontrib><creatorcontrib>Cahal, Michal</creatorcontrib><creatorcontrib>Shonfeld, Tommy</creatorcontrib><creatorcontrib>Prais, Dario</creatorcontrib><creatorcontrib>Levine, Hagit</creatorcontrib><creatorcontrib>Mei‐Zahav, Meir</creatorcontrib><creatorcontrib>Bar‐On, Ophir</creatorcontrib><creatorcontrib>Gendler, Yulia</creatorcontrib><creatorcontrib>Zalcman, Jonatan</creatorcontrib><creatorcontrib>Sarsur, Eahab</creatorcontrib><creatorcontrib>Aviram, Micha</creatorcontrib><creatorcontrib>Goldbart, Aviv</creatorcontrib><creatorcontrib>Stafler, Patrick</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric pulmonology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ehrlich, Shay</au><au>Golan Tripto, Inbal</au><au>Lavie, Moran</au><au>Cahal, Michal</au><au>Shonfeld, Tommy</au><au>Prais, Dario</au><au>Levine, Hagit</au><au>Mei‐Zahav, Meir</au><au>Bar‐On, Ophir</au><au>Gendler, Yulia</au><au>Zalcman, Jonatan</au><au>Sarsur, Eahab</au><au>Aviram, Micha</au><au>Goldbart, Aviv</au><au>Stafler, Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High flow nasal cannula therapy in the pediatric home setting</atitle><jtitle>Pediatric pulmonology</jtitle><addtitle>Pediatr Pulmonol</addtitle><date>2023-03</date><risdate>2023</risdate><volume>58</volume><issue>3</issue><spage>941</spage><epage>948</epage><pages>941-948</pages><issn>8755-6863</issn><eissn>1099-0496</eissn><abstract>Background
High‐flow nasal cannula (HFNC) therapy may be better tolerated than traditional noninvasive ventilation (NIV) and is rapidly gaining acceptance in pediatric acute care. In Israel, HFNC is approved for domestic use. We aim to describe its indications, efficacy, parental satisfaction, and safety.
Methods
Retrospective study of children treated with home HFNC therapy in three pediatric centers. Data included demographic parameters, indication of use, weight and days of hospitalization before and after initiation. Safety, tolerability, and parental satisfaction were assessed via standardized telephone questionnaire.
Results
Median (interquartile range [IQR]) age of initiating home HFNC in 75 children was 8.3 (2.2, 29.6) months. Indications were obstructive sleep apnea (33; 44%), airway malacia (19; 25%), chronic lung disease (15; 20%), neuromuscular disease (4; 5%), and postextubation support (4; 5%). Weight standard deviation score rose from −2.3 pre‐HFNC to −1.7 at 6.7 months post‐HFNC initiation, p < 0.001. Hospital admission days during the 2 months pre‐ versus post‐HFNC initiation were 22 (5.5, 60) and 5 (0, 14.7) respectively, p < 0.008. Median (IQR) parental satisfaction score was 5/5 (4, 5). Fifty of 60 (83%) respondents would recommend home HFNC to other families in a similar situation. There were no serious adverse events.
Conclusion
In our population, domestic HFNC appeared safe and well tolerated for a variety of indications. Its introduction was associated with improved weight gain, fewer hospitalization days and high parental satisfaction. Further work is required to characterize groups of children most likely to benefit from HFNC, as opposed to traditional modes of NIV.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36564183</pmid><doi>10.1002/ppul.26282</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8880-8212</orcidid><orcidid>https://orcid.org/0000-0001-6259-405X</orcidid><orcidid>https://orcid.org/0000-0002-6683-0264</orcidid><orcidid>https://orcid.org/0000-0002-4165-0144</orcidid><orcidid>https://orcid.org/0000-0002-7063-4653</orcidid><orcidid>https://orcid.org/0000-0001-7259-4539</orcidid><orcidid>https://orcid.org/0000-0001-6772-5784</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8755-6863 |
| ispartof | Pediatric pulmonology, 2023-03, Vol.58 (3), p.941-948 |
| issn | 8755-6863 1099-0496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2758114608 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Cannula Child chronic lung disease high flow nasal cannula home therapy Humans Noninvasive Ventilation Oxygen Inhalation Therapy pediatric Pediatrics Respiration, Artificial Respiratory Insufficiency - therapy Retrospective Studies |
| title | High flow nasal cannula therapy in the pediatric home setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T13%3A46%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20flow%20nasal%20cannula%20therapy%20in%20the%20pediatric%20home%20setting&rft.jtitle=Pediatric%20pulmonology&rft.au=Ehrlich,%20Shay&rft.date=2023-03&rft.volume=58&rft.issue=3&rft.spage=941&rft.epage=948&rft.pages=941-948&rft.issn=8755-6863&rft.eissn=1099-0496&rft_id=info:doi/10.1002/ppul.26282&rft_dat=%3Cproquest_cross%3E2758114608%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2776964058&rft_id=info:pmid/36564183&rfr_iscdi=true |